

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Monday, November 14, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L1	(igg2 or igg-2 or igg2a or igg2b or igg-2a or igg\$).ti,ab,clm.	7942
<input type="checkbox"/>	L2	L1 and (pylori or pyloir or pylon or pyloris or pyloridis or helicobacter or hpylori or h-pylori).ti,ab,clm.	89
<input type="checkbox"/>	L3	L2 and (cancer or malt or carcinoma or gastric or neoplasm or neo-plasm or carcin-oma or atypical).ti,ab,clm.	27

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 27 of 27 returned.**

-
- ☐ 1. [20050221284](#). 29 Dec 04. 06 Oct 05. Heteropolymer complexes and methods for their use. Taylor, Ronald P., et al. 435/5; 424/144.1 530/388.22 C12Q001/70 A61K039/395 C07K016/28.
-
- ☐ 2. [20050170409](#). 08 Feb 05. 04 Aug 05. Method and apparatus for increasing the dynamic range and accuracy of binding assays. Keys, Daniel A., et al. 435/6; 435/287.2 702/19 C12Q001/68 G06F019/00 G01N033/48 G01N033/50 C12M001/34.
-
- ☐ 3. [20040157277](#). 28 Oct 03. 12 Aug 04. Methods for predicting and/or diagnosing the risk of gastric cancer. Clancy, Robert Llewellyn, et al. 435/7.23; 435/7.32 G01N033/574 G01N033/554 G01N033/569.
-
- ☐ 4. [20040014708](#). 30 Jun 03. 22 Jan 04. Composition comprising immunogenic microparticles. Plebanski, Magdalena. 514/44; 424/184.1 424/188.1 424/189.1 424/191.1 514/54 A61K048/00 A61K039/38 A61K039/21 A61K039/29 A61K039/002 A61K031/715.
-
- ☐ 5. [20040001849](#). 07 Mar 03. 01 Jan 04. Antigen library immunization. Punnonen, Juha, et al. 424/186.1; 424/188.1 424/189.1 424/190.1 530/350 A61K039/12 A61K039/21 A61K039/29 A61K039/02 C07K014/16 C07K014/02 C07K014/195.
-
- ☐ 6. [20030078737](#). 24 Oct 01. 24 Apr 03. Method and apparatus for increasing the dynamic range and accuracy of binding assays. Keys, Daniel A., et al. 702/19; 435/7.1 G01N033/53 G06F019/00 G01N033/48 G01N033/50.
-
- ☐ 7. [20020198162](#). 10 Feb 99. 26 Dec 02. ANTIGEN LIBRARY IMMUNIZATION. PUNNONEN, JUHA, et al. 514/44; A61K031/70 A01N043/04.
-
- ☐ 8. [20020182600](#). 11 Apr 01. 05 Dec 02. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques. Smith, Jack V.. 435/6; C12Q001/68.
-
- ☐ 9. [6902743](#). 06 Apr 98; 07 Jun 05. Therapeutic treatment and prevention of infections with a bioactive material(s) encapsulated within a biodegradable-bio-compatible polymeric matrix. Setterstrom; Jean A., et al. 424/489; 424/451 424/470 424/482 424/490. A61K009/14 A61K039/40 A61K009/48 A61K009/26 A61K009/16.
-
- ☐ 10. [6867005](#). 24 Oct 01; 15 Mar 05. Method and apparatus for increasing the dynamic range and accuracy of binding assays. Keys; Daniel A., et al. 435/7.1; 435/286.1 435/287.2 435/288.7 436/164 436/172. G01N033/53.
-
- ☐ 11. [5567594](#). 20 Dec 93; 22 Oct 96. Methods and compositions for the detection and treatment of diseases associated with antigens of microorganisms. Calenoff; Emanuel. 435/7.32; 435/7.33 435/822 435/883 435/975 436/513 436/518. G01N033/53 G01N033/554 G01N033/569.
-
- ☐ 12. [WO2004056847A](#). Novel isolated human monoclonal antibody binding to human epidermal growth factor receptor, useful for treating diseases e.g. cancer, psoriasis, rheumatoid arthritis, systemic sclerosis, Crohn's disease, Alzheimer's disease. BAADSGAARD, O, et al. A61K039/395 C07K000/00

C07K016/28.

☐ 13. WO2003106685A. Recombinant Gram-positive bacterium useful for treating cancer or allergy, comprising modulation of gene expression involved in biosynthesis, modification or degradation of cell wall component, vector encoding polypeptide. DELCOUR, J, et al. A61K039/00 C12N015/74.

☐ 14. WO 200298368A. Novel immunogenic mutant cholera holotoxin for preparing immunogenic composition for enhancing immune response of vertebrate host to bacterial or viral antigen, has reduced toxicity compared to wild-type cholera toxin. GREEN, B A, et al. A61K000/00 A61K039/00 A61K039/002 A61K039/008 A61K039/02 A61K039/095 A61K039/102 A61K039/106 A61K039/12 A61K039/245 A61K039/35 A61K039/39 A61K039/42 C07K001/00 C07K014/00 C07K014/28 C07K017/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12P021/02.

☐ 15. US20020182600A. Detecting an analyte e.g. cocaine involves conjugating the nucleounits to indicator for the analyte forming nucleounit indicator conjugate and detecting the analyte of interest using the nucleounit indicator conjugate in a buffer. SMITH, J V. C12Q001/68.

☐ 16. WO 200296949A. Raising an immune response in an animal by administering composition comprising carrier and antigen bound to targeting moiety which binds to receptor present in circulatory vessels in Gut Associated Lymphoid tissue. BOYLE, J, et al. A61K039/00 A61K039/38 A61P037/04 C07K016/28.

☐ 17. US20020168380A. New polypeptides isolated from Mycobacterium vaccae, useful for treating e.g. mycobacterial infections, sarcoidosis, asthma, allergic rhinitis, chronic graft versus host disease, or systemic sclerosis. DELCAYRE, A. A61K039/00 A61K039/02 A61K039/04 A61K039/38.

☐ 18. WO 200240051A. Composition useful for the management of infection-associated disease e.g. gastrointestinal and joint diseases comprises colostrum or colostrum-derived product and hyperimmune milk or hyperimmune milk-derived product. HOBMAN, P G, et al. A61K031/7032 A61K031/739 A61K033/06 A61K035/20 A61K039/395 A61K045/06 A61P001/00 A61P001/04 A61P019/02 A61P029/00 A61P031/04.

☐ 19. WO 200187846A. New 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion useful as inhibitor of protein kinase activity. ARNOLD, L D, et al. A61K031/416 A61K031/4162 A61K031/4178 A61K031/4196 A61K031/427 A61K031/439 A61K031/4439 A61K031/454 A61K031/496 A61K031/506 A61K031/5377 A61K031/55 A61K031/69 A61P007/00 A61P007/02 A61P007/04 A61P009/00 A61P009/10 A61P011/00 A61P015/00 A61P017/00 A61P017/02 A61P017/06 A61P019/00 A61P019/02 A61P027/02 A61P027/06 A61P029/00 A61P031/04 A61P035/00 A61P037/08 A61P043/00 C07D211/68 C07D231/00 C07D231/54 C07D243/08 C07D401/04 C07D401/06 C07D401/12 C07D401/14 C07D403/00 C07D403/10 C07D403/12 C07D405/12 C07D409/04 C07D409/12 C07D409/14 C07D417/12 C07D451/02 C07D451/04 C07D491/048 C07D495/04 C07M007/00 C07M009/00.

☐ 20. WO 200125254A. Antagonist and adjuvant activity in vaccine preparation for enhancing immune response comprises a lipopolysaccharide isolated from a gram negative bacterium defective in at least msbB or htrB or their analog or derivative. CROWLEY, R, et al. A61K039/07 A61K039/38 C07K000/00 C12N001/00 C12N005/02 G01N033/53.

☐ 21. WO 200070348A. Diagnosis of gastric cancer, or assessment of the risk of developing it, using a largely non-invasive method which uses the level of e.g., gamma-interferon or interleukin-4, as a marker. CLANCY, R L, et al. C12Q001/02 C12Q001/68 G01N033/53 G01N033/554 G01N033/569

G01N033/574.

☐ 22. WO 200014240A. Attenuated gram-negative *Salmonella* cells, comprising inactivated genes in the SPI2 locus and useful for vaccinating against a range of disorders associated with microbial infections such as stomach and cervical cancers. APFEL, H, et al. A61K039/00 A61K039/02 A61K039/106 A61K039/112 A61K039/12 A61K039/245 A61K039/29 A61K048/00 A61P031/04 A61P031/12 A61P035/00 C07H021/02 C07H021/04 C07K014/005 C07K014/195 C07K014/235 C07K014/255 C07K014/47 C07K016/12 C07K019/00 C12N001/12 C12N001/21 C12N001:21 C12N007/00 C12N015/09 C12N015/31 C12N015/62 C12N015/63 C12N015/74 C12Q001/68 C12R001:42 G01N033/53 C12N001/21 C12N001/21 C12N001/21 C12R001:01 C12R001:42 C12R001:63 C12R001:42 C12N001/21.

☐ 23. US 6323008B. Production of sialyl-oligosaccharides, particularly sialyl-lactose - by treating a dairy source such as a cheese processing waste stream with an alpha (2-3) trans-sialidase. BARKER, W A, et al. A01K067/027 A23C009/12 C07H007/027 C12N005/10 C12N015/09 C12P001/00 C12P019/00 C12P019/04 C12P019/26 G01N033/00.

☐ 24. WO 9848836A. *Helicobacter*-derived immunogen for use as vaccine - containing extract of *Quillaja saponaria*, cationic lipid and/or glyco-lipo-peptide as adjuvant. GUY, B, et al. A61K039/02 A61K039/106 A61K039/39 A61K045/00 A61K047/00 A61P031/04 A61K039/02 A61K047:26 A61K047:42.

☐ 25. EP 946874B. Detection of *Helicobacter pylori* infection - by detecting reactivity of samples with *H. pylori* type-common antigens and type-specific *H. pylori* Type I antigens. POLITO, A, et al. G01N033/543 G01N033/554 G01N033/569.

☐ 26. EP 824357B. Use of epidermal growth factor to control intestinal colonisation by pathogens - also increases e.g. weight gain and intestinal absorption of IgG, and also use of epidermal growth factor inhibitor to reduce e.g. weight gain. BURET, A G, et al. A23K001/16 A61K031/275 A61K038/18 A61K038/22 A61K045/00 A61P001/04 A61P001/12 A61P003/04 A61P031/04 C07K002/00 C07K014/485.

☐ 27. EP 439462B. High mol. wt. cell-associated *Campylobacter pylori* protein - used as antigens for serological detection of *C. pylori* infection. EVANS, D G, et al. A61K039/39 C07K001/14 C07K003/02 C07K014/205 C07K015/00 C12P021/00 C12Q001/00 C12Q001/58 G01N033/53 G01N033/531 G01N033/543 G01N033/569 C12P021/00 C12R001:01.

[Generate Collection](#)
[Print](#)

Term	Documents
CANCER	196719
CANCERS	53350
MALT	22174
MALTS	537
CARCINOMA	52335
CARCINOMAS	20442
GASTRIC	52371

GASTRICS	3
NEOPLASM	6234
NEOPLASMS	13872
NEO-PLASM	4
(L2 AND (CANCER OR MALT OR CARCINOMA OR GASTRIC OR NEOPLASM OR NEO-PLASM OR CARCIN-OMA OR ATYPICAL).TI,AB,CLM.).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	27

There are more results than shown above. Click here to view the entire set.

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

DERWENT-ACC-NO: 1999-009388

DERWENT-WEEK: 200258

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Helicobacter-derived immunogen for use as vaccine - containing extract of Quillaja saponaria, cationic lipid and/or glyco-lipo-peptide as adjuvant

Basic Abstract Text (1):

A composition (I) comprises: (A) an immunogenic agent derived from Helicobacter; and (B) at least one adjuvant chosen from (i) purified saponins from an extract of Quillaja saponaria; (ii) cationic lipids (or their salts) which are weak inhibitors of protein kinase C and have a structure including a lipophilic group derived from cholesterol, a carboxamide or carbamoyl linking group, a spacer arm consisting of a 1-20C alkyl chain and a cationic amine group (primary, secondary, tertiary or quaternary), provided that the lipids are not present in the form of liposomes when (I) contains neither (i) nor (ii); and (iii) glyco-lipo-peptides of formula (II). R1 = 1-50C alkyl (optionally unsaturated); X = -CH₂-, -O- or -NH-; R2 = H or as R1; R3-R5 = H or acyl-CO-R6; R6 = 1-10C alkyl; R7 = H, 1-7C alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-(methylthio)-ethyl, 3-aminopropyl, 3-ureido-propyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoylethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl or 4-imidazolylmethyl; R8 = H or methyl; R9 = H, acetyl, benzoyl, trichloroacetyl, trifluoroacetyl, methoxycarbonyl, t-butoxycarbonyl or benzyloxycarbonyl; or R7 + R8 = -(CH₂)₃-.

Basic Abstract Text (2):

USE - (I) is useful as a vaccine for the treatment or prevention of Helicobacter infections, e.g. H. pylori infections in humans (associated with gastric and duodenal ulcers, gastritis and gastric carcinoma). (I) induces an immune response of the T-helper 1 type (Th 1) against Helicobacter (claimed).

Basic Abstract Text (3):

ADVANTAGE - (I) gives a strong Th 1 response on systemic administration and a degree of protection at least equivalent to that obtained using the mucosal route and a bacterial toxin adjuvant. Specifically the Th 1 immune response measured in the mouse gives IgG2a:IgG1 and IgG2a:IgA ELISA titre ratios of at least 1:100, preferably at least 1:2 (claimed).